Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Feb 21, 2019 8:29am

121 Views

Post# 29392542

RE:RE:Revenues a little light....let’s hear the call

Pretty much what I was saying yeterday and taking flack for.

That being said, Egrifta growth should be better going forward with F4.

The key will be highlighting Trogarzo growth in the curretn quarter.....which is almost over!

The market needs to look forward....

bfw

smartmichel wrote: Back to red... disapointed.
To avoid a new 52w low today, the c.c. must:
-Underline where we are today about Trogarzo: hockey stick inflexion...
-Give serious target for fiscal 2019...
-Where we are about F4...
-Where we are about Europe and explain how this adventure it will be profitable...
-Where we are about 3rd drug research...

Is it the last Luc's c.c.??